Skip to main content
Caplight Logo









KYAN Technologies

KYAN Technologies

Private
SingaporeHealthcare & Life Scienceshttps://kyantechnologies.com/

Last Round

VC Round

May 1, 2025

Total Funding Raised

$5M

Company Overview

KYAN Technologies is a biotechnology company that provides a functional precision medicine platform, Optim.AI™, which uses small data AI and biological experiments to identify optimal drug-dose combinations for cancer therapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Medical AI, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Usage-Based SaaS

AI Layer

Application

Keywords

precision medicineoncology diagnosticslaboratory-developed testLDTfunctional precision medicinedrug response predictionsmall-data AIex vivo testingclinical decision supportbiomarker discoverycancer drug discoverypersonalized cancer treatmentAI-driven drug discoverybiobankdigital twin oncology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

KYAN Technologies Comparables

Compare KYAN Technologies with similar companies based on industry and business-model similarity.

KYAN Technologies comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Travera
83%
Apricot Therapeutics AG
82%
Pear Bio
81%

KYAN Technologies Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundMay 1, 2025
Pre SeedOct 26, 2022

Key People

Founding team and executive leadership

Hugo Saavedra

Co Founder, Chief Executive Officer, Member Board Of Directors

Founding Team

KYAN Technologies Investors

Notable investors and investment history

KYAN Technologies investors
InvestorRounds
SEEDS CapitalPre Seed
K3 VenturesPre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 1, 2025

    $6.5M raised in a VC Round.

  • Apr 15, 2025

    KYAN Technologies announced it will present two abstracts on its Optim.AI functional precision medicine platform at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30 in Chicago, Illinois.

KYAN Technologies Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

KYAN Technologies Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about KYAN Technologies's valuation, stock price, and market status.

Firmographic Details

HeadquartersSingapore
Employee Range25
Year Founded2022
Last FundingMay 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?